ARTICLE | Company News
Amgen, J&J deal
April 11, 2016 7:00 AM UTC
The Janssen Research & Development LLC unit of Johnson & Johnson said it will discontinue its Phase III development program for osteoarthritis pain candidate fulranumab due to “strategic portfolio pri...